Status:
UNKNOWN
Re-evaluation of Donor-specific Anti-HLA Alloantibodies Immunoassay After Organ Transplantation, From Antigen Level to Epitope Level
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Organ Transplantation
Eligibility:
All Genders
7+ years
Brief Summary
Transplantation is the only treatment for end-stage organ dysfunction, with dialysis for the kidney. However, donor / recipient (D / R) tissue incompatibility accounts for the majority of long-term gr...
Eligibility Criteria
Inclusion
- patients (adults and children)
- patients recipients in France from 2008 to 2015 of a first kidney transplant / heart / lung / liver donor living or deceased, non-immunized anti-HLA before the transplant
- patients having preserved their graft \> 2 years
- having agreed to the use for research purposes in transplantation of the remains of the DNA and serum samples taken as part of the care of which the remains are available
Exclusion
- no inclusion if one of the inclusion criteria is not met
Key Trial Info
Start Date :
May 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2025
Estimated Enrollment :
20000 Patients enrolled
Trial Details
Trial ID
NCT03861962
Start Date
May 1 2019
End Date
May 1 2025
Last Update
April 29 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.